Karin L. Klingman

4.1k total citations · 1 hit paper
51 papers, 2.4k citations indexed

About

Karin L. Klingman is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Karin L. Klingman has authored 51 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 27 papers in Virology and 11 papers in Emergency Medicine. Recurrent topics in Karin L. Klingman's work include HIV/AIDS Research and Interventions (31 papers), HIV Research and Treatment (27 papers) and HIV/AIDS drug development and treatment (27 papers). Karin L. Klingman is often cited by papers focused on HIV/AIDS Research and Interventions (31 papers), HIV Research and Treatment (27 papers) and HIV/AIDS drug development and treatment (27 papers). Karin L. Klingman collaborates with scholars based in United States, South Africa and India. Karin L. Klingman's co-authors include Timothy F. Murphy, John W. Mellors, Robert L. Murphy, Sharon A. Riddler, Richard Haubrich, James F. Rooney, Kevin W. Garren, Diane V. Havlir, A. Gregory DiRienzo and William G. Powderly and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Karin L. Klingman

48 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

2008 500 citations Sharon A. Riddler, Richard Haubrich et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Karin L. Klingman

Since Specialization

Citations

This map shows the geographic impact of Karin L. Klingman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin L. Klingman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin L. Klingman more than expected).

Fields of papers citing papers by Karin L. Klingman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin L. Klingman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin L. Klingman. The network helps show where Karin L. Klingman may publish in the future.

Co-authorship network of co-authors of Karin L. Klingman

This figure shows the co-authorship network connecting the top 25 collaborators of Karin L. Klingman. A scholar is included among the top collaborators of Karin L. Klingman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin L. Klingman. Karin L. Klingman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy 2021 ·Open Forum Infectious Diseases ·Rachel M. Presti, (unknown), Brett Williams, Alan Landay, Jeffrey M. Jacobson, Cara C. Wilson, Carl J. Fichtenbaum, Netanya S. Utay, Michael P. Dubé, Karin L. Klingman, Jacob D. Estes, Jacob K. Flynn, Amanda H. Loftin, Jason M. Brenchley, Adriana Andrade, Douglas Kitch, Edgar T. Overton	12
2	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) 2019 ·American Heart Journal ·Steven Grinspoon, Kathleen V. Fitch, Edgar T. Overton, Carl J. Fichtenbaum, Markella V. Zanni, Judith A. Aberg, Carlos Malvestutto, Michael T. Lu, Judith S. Currier, Craig A. Sponseller, Myron A. Waclawiw, Beverly Alston‐Smith, Katharine Cooper‐Arnold, Karin L. Klingman, Patrice Desvigne‐Nickens, Udo Hoffmann, Heather J. Ribaudo, Pamela S. Douglas	89
3	Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy 2018 ·AIDS ·Robert C. Kalayjian, Jeffrey M. Albert, Serge Cremers, Samir K. Gupta, Grace A. McComsey, Karin L. Klingman, Carl J. Fichtenbaum, Todd T. Brown, Babafemi Taiwo	7
4	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial 2017 ·The Lancet HIV ·Jemma L. O’Connor, Michael J. Vjecha, Andrew Phillips, Brian Angus, David A. Cooper, Beatriz Grinsztejn, Gustavo Lopardo, Satyajit Das, Robin Wood, Aimee Wilkin, Hartwig Klinker, Pacharee Kantipong, Karin L. Klingman, David Jilich, (unknown), Eileen Denning, Ibrahim Abubakar, Fred M. Gordin, Jens Lundgren	35
5	Differential CD4+ cell count increase and CD4+ 2016 ·AIDS ·Ellen S. Chan, Alan Landay, Todd T. Brown, Heather J. Ribaudo, Paria Mirmonsef, Igho Ofotokun, M. Neale Weitzmann, Jeffrey Martinson, Karin L. Klingman, Joseph J. Eron, Carl J. Fichtenbaum, Jill Plants, Babafemi Taiwo	6
6	HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors 2015 ·Annals of Internal Medicine ·Karen T. Tashima, Laura Smeaton, Carl J. Fichtenbaum, Adriana Andrade, Joseph J. Eron, Rajesh T. Gandhi, Victoria A. Johnson, Karin L. Klingman, Justin Ritz, Sally Hodder, Jorge Santana, Timothy Wilkin, Richard Haubrich, (unknown)	11
7	Addressing Standards of Care in Resource-Limited Settings 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Liza Dawson, Karin L. Klingman, Jeanne Marrazzo	9
8	Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings 2012 ·AIDS ·John Bartlett, Heather J. Ribaudo, Carole L. Wallis, Evgenia Aga, David Katzenstein, Wendy Stevens, Michael Norton, Karin L. Klingman, Mina C. Hosseinipour, John A. Crump, Khuanchai Supparatpinyo, Sharlaa Badal‐Faesen, Beatrice Kallungal, Nagalingeswaran Kumarasamy	32
9	Quality of Life Among Individuals with HIV Starting Antiretroviral Therapy in Diverse Resource-Limited Areas of the World 2011 ·AIDS and Behavior ·Steven A. Safren, Ellen Hendriksen, Laura Smeaton, David D. Celentano, Mina C. Hosseinipour, Ronald L. Barnett, Juan V. Guanira, Timothy Flanigan, N Kumarasamy, Karin L. Klingman, Thomas Campbell	38
10	Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection 2011 ·AIDS ·Richard Haubrich, Sharon A. Riddler, (unknown), (unknown), Karin L. Klingman, Kevin W. Garren, D. Butcher, James F. Rooney, Diane V. Havlir, John W. Mellors	19
11	A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study 2011 ·HIV Clinical Trials ·Mary Albrecht, Aprateem Mukherjee, Camlin Tierney, Gene D. Morse, Carrie Dykes, Karin L. Klingman, Lisa M. Demeter	7
12	Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mary Vogler, Kristine B. Patterson, Lori Kamemoto, Jeong-Gun Park, Heather Watts, Francesca Aweeka, Karin L. Klingman, Susan E. Cohn	42
13	Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment 2009 ·AIDS ·Richard Haubrich, Sharon A. Riddler, A. Gregory DiRienzo, Lauren Komarow, William G. Powderly, Karin L. Klingman, Kevin W. Garren, D. Butcher, James F. Rooney, David W. Haas, John W. Mellors, Diane V. Havlir	210
14	A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients 2009 ·AIDS ·Lisa M. Demeter, Hongyu Jiang, Aprateem Mukherjee, Gene D. Morse, Robin DiFrancesco, Robert DiCenzo, Carrie Dykes, Prakash Sista, Lee T. Bacheler, Karin L. Klingman, Alex R. Rinehart, Mary Albrecht	14
15	Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV 2008 ·HIV Clinical Trials ·Ann C. Collier, Camlin Tierney, Gerald Downey, Susan H. Eshleman, Angela D. M. Kashuba, Karin L. Klingman, Emanuel N. Vergis, Gary E. Pakes, James F. Rooney, Alex R. Rinehart, John W. Mellors, (unknown)	8
16	Class-Sparing Regimens for Initial Treatment of HIV-1 Infection breakdown → 2008 ·New England Journal of Medicine ·Sharon A. Riddler, Richard Haubrich, A. Gregory DiRienzo, Lynne Peeples, William G. Powderly, Karin L. Klingman, Kevin W. Garren, (unknown), James F. Rooney, Barbara Brizz, Umesh Lalloo, Robert L. Murphy, Susan Swindells, Diane V. Havlir, John W. Mellors	500
17	Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results 2005 ·AIDS ·Angela D. M. Kashuba, Camlin Tierney, Gerald Downey, Edward P. Acosta, Emanuel N. Vergis, Karin L. Klingman, John W. Mellors, Susan H. Eshleman, Trevor R. Scott, Ann C. Collier	48
18	Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection 2004 ·New England Journal of Medicine ·Roy M. Gulick, Heather J. Ribaudo, Cecilia M. Shikuma, Stephanie Lustgarten, Kathleen Squires, William A. Meyer, Edward P. Acosta, Bruce R. Schackman, Christopher D. Pilcher, Robert L. Murphy, William E. Maher, Mallory D. Witt, Richard C. Reichman, Sally Snyder, Karin L. Klingman, Daniel R. Kuritzkes	396
19	Genetic Diversity among Strains of Moraxella catarrhalis : Analysis Using Multiple DNA Probes and a Single-Locus PCR-Restriction Fragment Length Polymorphism Method 1998 ·Journal of Clinical Microbiology ·Elaine S. Walker, Robert A. Preston, J. Christopher Post, Garth D. Ehrlich, John H. Kalbfleisch, Karin L. Klingman	22
20	Dynamics of Respiratory Tract Colonization by Branhamella Catarrhalis in Bronchiectasis 1995 ·American Journal of Respiratory and Critical Care Medicine ·Karin L. Klingman, Anita Pye, Timothy F. Murphy, Susan L. Hill	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact